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Atrial  fibrillation  (AF),  both  valvular  and 
non-valvular, carries an increased risk of stroke and 
systemic embolism, which leads to major social and 
economic burden. Without thromboprophylaxis, stroke 
risk averages four per cent/year among patients with 
non-valvular AF and 17-18 per cent/year among 
patients with valvular AF1. Anticoagulation reduces 
this risk by 64 per cent compared to placebo and halves 
the risk compared with antiplatelet therapy2,3. The cost 
of  treating  stroke  can  be  ₹500,000  in  the  first  year4, 
a major burden given the 1.44-1.64 million strokes 
diagnosed each year in India alone5.
In most of the rural India, warfarin is the only 
oral anticoagulant available, but there are many 
barriers to its optimal use. Warfarin requires frequent 
monitoring and adjustment to maintain a therapeutic 
range. Subtherapeutic values increase the risk of 
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Background & objectives: In most of rural India, warfarin is the only oral anticoagulant available. 
Among patients taking warfarin, there is a strong association between poor control of the international 
normalized ratio (INR) and adverse events. This study was aimed to quantify INR control in a secondary 
healthcare system in rural Chhattisgarh, India.
Methods: The INR data were retrospectively obtained from all patients taking warfarin during 2014-2016 
at a secondary healthcare system in rural Chhattisgarh, India. Patients attending the clinic had their INR 
checked at the hospital laboratory and their warfarin dose adjusted by a physician on the same day. The 
time in therapeutic range (TTR) was calculated for patients who had at least two INR visits.
Results: The 249 patients had 2839 INR visits. Their median age was 46 yr, and the median body mass 
index was 17.7 kg/m2. They lived a median distance of 78 km (2-3 h of travel) from the hospital. The 
median INR was 1.7 for a target INR of 2.0-3.0 (n=221) and 2.1 for a target of 2.5-3.5 (n=28). The median 
TTR was 13.0 per cent, and INR was subtherapeutic 66.0 per cent of the time. Distance from the hospital 
was not correlated with TTR.
Interpretation & conclusions: INR values were subtherapeutic two-thirds of the time, and TTR values 
were poor regardless of distance from the health centre. Future studies should be done to identify 
interventions to improve INR control.
Key words Anticoagulation - international normalized ratio - stroke - TTR - warfarin
Indian J Med Res 152, September 2020, pp 303-307
DOI: 10.4103/ijmr.IJMR_1201_18
Quick Response Code:
[Downloaded free from http://www.ijmr.org.in on Monday, November 16, 2020, IP: 128.252.79.225]
304  INDIAN J MED RES, SEPTEMBER 2020
stroke and embolism in patients with AF6, whereas 
supratherapeutic values increase the risk of intracranial 
haemorrhage. Alternatives such as direct oral 
anticoagulants  (DOACs)  are  as  effective as warfarin, 
but these are prohibitively expensive for most rural 
Indians and not approved for use in patients with severe 
mitral stenosis or mechanical heart prostheses7.
Time in therapeutic range (TTR) is the standard 
method of estimating the quality of anticoagulation 
with warfarin8, and a goal of 70 per cent or more 
improves outcomes9. Although some anticoagulation 
clinics in high-income countries could meet this goal10, 
US clinics average was 55 per cent11, and outside of 
North America and Europe, TTR was often lower 
including 46.5 per cent in South Africa and 50.1 in 
Latin America12-14. Compared to patients with a TTR 
of approximately >70 per cent, patients with a TTR 
of approximately <50 per cent have double the risk of 
ischaemic stroke, bleeding or death15.
Of the 45 countries that enrolled participants in 
the ROCKET-AF trial, India had the lowest TTR of 
any region, averaging 35.9 per cent14. These data were 
collected from an urban centre, a setting with more 
robust healthcare infrastructure than rural India. The 
present study was aimed to characterize the quality 
of anticoagulation with warfarin in a rural, secondary 
healthcare system in Chhattisgarh, India, by quantifying 
the TTR of warfarin patients and determining the 
correlation of TTR with factors such as socio-economic 
status, caste and distance from the hospital.
Methods
This was a retrospective observational study. 
De-identified data were obtained from the Jan Swasthya 
Sahyog (JSS) electronic medical record (EMR). All 
patients who received warfarin between 2014 and 
2016 at JSS or its subcentres were included. Patients 
who lacked two or more INR values in any eight-week 
period were excluded from the analysis.
Demographic, clinical and laboratory data were 
abstracted from the EMR for all patients. Indication 
for warfarin was abstracted manually. Distance to 
the medical centre was ascertained from Google 
Maps. All patients who had INR measured at least 
twice during an eight-week period were included. 
A Behnk Elektronik’s Thrombostat magnet-based 
monitor (Norderstedt, Germany) was used to 
measure INR values. Patients attending the clinic had 
their INR checked in the hospital laboratory prior to 
their appointments, and the results were uploaded 
into the EMR by the time of their appointment 1-3 h 
later. Warfarin was adjusted by the physician on the 
same day after seeing and interviewing the patient 
in the clinic.
Ethical approval for the study was obtained by 
the Ethics Committee of the Emmanuel Hospital 
Association, New Delhi and by the Washington 
University School of Medicine’s IRB (#201612042).
Mean TTR was determined using the Rosendaal 
linear interpolation method8. Analyses were done using 
SAS version 9.4 (SAS Institute, Cary, NC, USA) and 
SPSS version 25 (IBM Corp., Armonk, NY, USA). 
Results
Demographic information of the patients is 
shown in Table I. There were 249 patients receiving 
warfarin, and 162 of them had more than one INR 
visit (87 were excluded as they did not have at least 
two INR readings in any eight-week period). There 
was a median of nine INR visits per included patient 
during the three-year study period. The median age 
was 46 yr; 135 (54.2%) were female, and the median 
body mass index was 17.7 kg/m2. Most patients were 
form Chhattisgarh (n=175, 70.3%) and the remaining 
were from Madhya Pradesh. Most patients were in the 
scheduled tribe (ST, n=86, 34.5%) or other backward 
class groups (OBC, n=86, 34.5%); 44 (7.7%) were 
from scheduled caste group. The median distance from 
the main JSS hospital was 78 km, which was slightly 
lower (72 km) among patients with two or more INR 
values greater than eight week apart. Indication for 
warfarin is shown in Table II. Most patients (62.6%) 
required warfarin for AF, and 10.0 per cent of patients 
had mechanical valves. The median INR was 1.7 for 
patients whose target INR was 2.0-3.0 and 2.1 for 
those with a target of 2.5-3.5 (Table II). Most (n=221, 
88.8%) patients had a target INR of 2.0-3.0 and 11.2 
per cent (n=28) had a target of 2.5-3.5. All patients 
with the higher target had mechanical mitral valve 
replacements (MVRs). The median TTR of the entire 
group of patients was 13.0 per cent (IQR 0-34.8). 
The median time subtherapeutic was 77.5 per cent 
(45-100), and the median time supratherapeutic 
was 0.0 per cent (0-11.6). Distance showed no 
correlation with TTR (Spearman’s rho <1%). TTR 
was greatest among the scheduled caste [median 26.4 
(IQR 10.7-44.5)] and lowest among scheduled tribes 
(median 0.0, IQR 0-13.4, P<0.001). Median TTR 
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Discussion
Our study demonstrated that the quality of 
anticoagulation in rural Chhattisgarh was poor. Overall, 
TTR was very low with a median of 13.0 per cent. The 
low TTR is a cause of concern because among patients 
taking warfarin, mortality rises with lower TTR, 
with the highest mortality seen in patients with <30 
per cent TTR16. Several factors may have contributed 
to the low TTR in this rural population such as lack of 
infrastructure and poverty. Although we hypothesized 
that distance also would contribute to low TTR, 
there was no correlation between distance and TTR. 
One  explanation  for  this  negative  finding  is  that 
distance may not  capture  the  difficulty  of  reaching 
the healthcare centre in terms of mode of transport 
(private vehicle, public transport or on foot), lost 
wages, childcare or cost of travel. However, a more 
likely explanation may be that in an area where poor 
public health infrastructure is ubiquitous, being 
closer to an overwhelmed institution makes little 
difference compared to being farther away.
Poverty also might have interfered with INR 
control. TTR correlates with socio-economic level17, 
and higher TTRs have been noted in anticoagulation 
clinics in high-income countries10. TTR increased in 
countries that implemented warfarin management 
programmes18. However, a more sustainable, long-term 
solution for rural India may lie in focusing on bolstering 
the public health infrastructure rather than establishing 
warfarin management programmes alone. Targeting 
women may also improve impact, as women are known 
to have poorer INR control than men19.
The TTR was low because patients spent 
77.5 per cent of their time below their target INR. 
The  effectiveness  of  warfarin  therapy  declines 
exponentially with subtherapeutic INR values, both in 
patients with AF20 and among those with mechanical 
valves21. Thus, these patients with subtherapeutic TTR 
Table I. Details of patients included in the study
Demographics n (%) Median IQR
Age (yr) 249 46 36-53
Height (cm) 222 155 250-162
Weight (kg) 226 47.7 39.3-54.8
BMI (kg/m2) 188 17.7 13.1-20.8
Distance (km) 249 78 33-149
Distance (km) (for patients with a TTR) 162 72 28-143
BMI, body mass index; IQR, interquartile range; TTR, time in therapeutic range
Table II. Indications for warfarin, INR targets, and median 
INRs in the study patients
Indication for warfarin n (%)
AF without mechanical valve 156 (62.6)
Mechanical valve 25 (10.0)
LA or LV thrombus 12 (4.8)
DVT, PE or DVT prophylaxis 54 (21.6)
Unclear 2 (0.8)
Target INR
2.0-3.0 221 (88.8)
2.5-3.5 28 (11.2)
INR (target 2-3), median (IQR) 1.7 (1.2-2.4)
INR (target 2.5-3.5), median (IQR) 2.1 (1.6-2.8)
INRs per person, median (IQR) 9 (3-19)
AF,  atrial  fibrillation;  LA,  left  atrial;  LV,  left  ventricular; 
DVT, deep-vein thrombosis; PE, pulmonary embolism; INR, 
international normalized ratio
Table III. Time in therapeutic range
TTR Median (%) IQR
Median TTR 13.0 0-34.8
Time below range 77.5 45.0-100.0
Time above range 0.0 0-11.6
TTR by caste
General category 11.3 0-34.7
OBC 20.0 0-35.6
SC 26.4 10.7-44.5
ST 0.0 0-13.4
Other 2.8 2.8-37.3
TTR versus distance Spearman’s ρ=0.009, P=0.906
SC, scheduled caste; ST, scheduled tribe; OBC, other 
backward  class
in OBCs was 20.4 (0-35.6) and 11.3 (0-34.7) in the 
general category patients (Table III). 
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received only a fraction of the potential benefit of their 
warfarin therapy and would have high risks of stroke, 
which could be reduced with better INR control.
The DOAC therapy, if available, would have been 
an option for up to 84.2 per cent (210 of 249) of these 
patients based on their indication for anticoagulation. 
Warfarin is a fraction of the upfront cost of DOACs, but 
has a greater monitoring burden and risk of intracranial 
haemorrhage22. Although DOACs are not cost saving, 
but these appear cost-effective among populations that 
have low TTR values with warfarin23. 
Patient self-testing may also be an option to 
improve INR control. In a US Veteran’s Affairs study, 
INR control was improved among patients who used 
individual home point-of-care (POC) devices, even 
when they had access to a managed anticoagulation 
clinic24. Though individual POC devices would be very 
expensive for the rural poor, a POC device shared in a 
rural community (perhaps with the help of a community 
health worker) could improve laboratory and clinical 
outcomes. 
Reducing the thrombotic tendency of mechanical 
valves may also lead to improved TTR. The newly 
designed On-X valve, for example, requires an INR 
of only 1.5-2.025, which was common in this study. 
If these valves were available for the rural poor who 
required a MVR, their risk of stroke might decline.
The study had several limitations. First, only 162 
of the 249 patients on warfarin had more than one visit, 
allowing TTR to be calculated. It is unknown which 
of the excluded patients established care elsewhere 
and continued to take warfarin and who discontinued 
warfarin. It is possible that because of this loss to 
follow up, INR monitoring may actually be worse than 
reported. Second, some patients might have run out of 
warfarin for several days before they were seen in clinic, 
which would have exaggerated the amount of time that 
they were presumed to be subtherapeutic. Third, as we 
did not have data on income or education level, we 
used caste as a surrogate marker of socio-economic 
status. Although several studies show that health 
indicators vary by caste26, it would have been better 
to have additional socio-economic variables. Finally, 
we did not assess whether dietary factors contributed 
to the subtherapeutic INR values in this population. 
In a previous study, dietary vitamin K has had an 
inconsistent effect on the therapeutic warfarin dose27.
In conclusion, the quality of anticoagulation in 
rural Chhattisgarh was below standards, even among 
patients with access to JSS health centres. Future 
studies should focus on identifying potential 
interventions in this population, such as access to 
POC monitoring, genetic risk-based dosing, DOAC 
therapy and the overall improvement of public health 
infrastructure in this neglected area.
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